About EnliTISA
EnliTISA’s vision is to improve the lives of patients with inflammatory and fibrotic diseases through the discovery and development of breakthrough therapies.
EnliTISA is a clinical stage biopharmaceutical company focused on developing novel therapeutics with a primary focus on inflammatory and fibrotic conditions with unmet medical needs.
EnliTISA, based in Shanghai, China, was founded by Chinese and Swedish team members in 2021, and is focusing on anti-inflammatory and anti-fibrosis multi-innovative drug development. The Chinese-Swedish team collaborates on pre-clinical and clinical development of drugs in China, Europe and the US.
All projects in the pipeline are based on the inventions made by the EnliTlSA team. As of now, 16 international PcT invention patents have
been applied for, 3 Chinese invention patents have been granted, and 18 international invention patents have been granted.
Founded in
International invention patents
- ARDS: Phase II clinical trials are underway in China, with completion of patient enrollment anticipated by March 2025.
- COPD: Preparations are ongoing to submit applications for clinical trial authorization.
- IPF: Phase I clinical trials have been completed in Europe.
- SOM: A Phase Ib clinical trial has been initiated in China, expected to conclude in the second quarter of 2025.
- Montelukast Sodium Gel, a highly potent, low-toxicity, and safe leukotriene receptor antagonist, has expanded its therapeutic scope through formulation innovation. It is now indicated for postoperative hemorrhoid care, burn wounds, chronic wounds, and radiation proctitis. The development and production rights for these four indications in mainland China have been licensed to Shanghai Pharmaceutical (Group) Co., Ltd.. To date, Phase IIa clinical trials have been completed for postoperative hemorrhoid management and radiation proctitis.
Organizational
Our team
Co-founders
Bengt Ingemar Samuelsson
Nobel Prize winner, second largest shareholder, director of Shanghai company, chairman of Sweden subsidiary
· Rich accumulation of basic research on inflammation: 1982 Nobel Prize in Physiology or Medicine: Prostaglandins and related active substances · Rich experience in transformation of achievements: Originally developed montelukast sodium, celecoxib, Xlata, etc., and cooperated with Pfizer and Merck; served as director of 12 internationally renowned pharmaceutical companies and investment companies · Broad vision for basic research and industrial innovation: 12 years as dean of Karnarinska Institute in Sweden; 12 years as chairman of Nobel Foundation; nomination rights for Nobel Prize; Galen Award Jury
Jan-Christer Janson
Founding shareholder, director of Shanghai company, director of Sweden subsidiary
· Former Chief Scientist of Swedish Pharmacia Company · Protein and peptide purification and modification scientists · Winner of the International Science and Technology Cooperation Award of the People's Republic of China · Winner of Chinese Government Friendship Award
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Leadership Team
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Ru Hui
Ru Hui
Lars Öhman
Lars Öhman
Board members of EnliTISA Shanghai or Swedish daughter company
Bengt Ingemar Samuelsson
Nobel Prize winner, second largest shareholder, director of Shanghai company, chairman of Sweden subsidiary
· Rich accumulation of basic research on inflammation: 1982 Nobel Prize in Physiology or Medicine: Prostaglandins and related active substances · Rich experience in transformation of achievements: Originally developed montelukast sodium, celecoxib, Xlata, etc., and cooperated with Pfizer and Merck; served as director of 12 internationally renowned pharmaceutical companies and investment companies · Broad vision for basic research and industrial innovation: 12 years as dean of Karnarinska Institute in Sweden; 12 years as chairman of Nobel Foundation; nomination rights for Nobel Prize; Galen Award Jury
Jan-Christer Janson
Founding shareholder, director of Shanghai company, director of Sweden subsidiary
· Former Chief Scientist of Swedish Pharmacia Company · Protein and peptide purification and modification scientists · Winner of the International Science and Technology Cooperation Award of the People's Republic of China · Winner of Chinese Government Friendship Award
Jesper Zacharias Haeggstrom
Core member, director of Swedish subsidiary; Professor Samuelsson
· Focus on basic research on inflammation, including new target research; deeply cultivate the basis of arachidonic acid inflammation, and discover drug candidates from substances produced by the human body to fight inflammation and damage · Vice-Chairman of the Nobel Prize Review Committee for Medical Physiology
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Scientific affair & regulatory affair team
Anders Kärnell
Anders Kärnell
Jiang Taotao (Cathy)
Jiang Taotao (Cathy)
Kang Ruijuan (Alicia)
Kang Ruijuan (Alicia)
Culture
Enlitisa
Corporate Mission
To be an original research and innovation drug enterprise with strong vitality and fighting power
Corporate Vision
To be an original research and innovation drug enterprise with strong vitality and fighting power, and repay the support of shareholders, society and the government with good drugs and taxes that can withstand the years
Property
Authorized Patent of Invention (US)
Authorized Patent of Invention (CN)
Authorized Patent of Invention (CN)
Authorized Patent of Invention (CN)
Honor
2024 Shanghai Top 50 Most Investment-Promising Startups
Top 50 Innovation & Entrepreneurship Enterprises list of the China Innovation & Entrepreneurship Competition
Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix
National High-tech Enterprise
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn